ArticleAmerican journal of translational research2026
Cause-specific mortality beyond prostate cancer in young men: a population-based study of second malignancies and non-tumor causes.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the cause-specific mortality patterns in young people (<50 years) diagnosed with prostate cancer (PCa).
methodsUsing the Surveillance, Epidemiology, and End Results (SEER) database, we identified young PCa patients diagnosed between 2000 and 2018. Causes of death were analyzed, and standardized mortality ratios (SMRs) were calculated. An independent clinical cohort (n=200) was used for external validation.
resultsAmong 19,352 patients with localized PCa, 1,177 deaths were observed, of which 21.4% were due to pCAs, 22.9% to site-specific malignancies (SMTs), and 55.7% to other non-tumor causes. Colorectal cancer exhibited a significantly reduced mortality risk among SMTs (SMR: 0.67) compared to the general population. Heart disease (SMR: 0.67) was the leading non-cancer cause of death. In 4,445 individuals with regional PCa, 540 deaths were observed, with PCa-specific causes accounting for 54.6%. Lung cancer mortality was significantly reduced (SMR: 0.51). Among 1,070 patients with metastatic PCa, 769 deaths were recorded, with 87.6% attributed to PCa. This stage-specific mortality pattern was consistently validated in the independent clinical cohort.
conclusionsCause-specific mortality among young PCa patients varies substantially by disease stage at diagnosis. Non-PCa causes predominate in patients with localized disease, whereas PCa remains the principal cause of death in metastatic cases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.